By far the largest provider of comprehensive virtual healthcare, Teladoc Health generated over $1.09 billion in revenue in 2020 and provides a good case to explore the telehealth industry. Teladoc, like many in the industry, benefited enormously from the 2020 pandemic in the form of increased revenue and a rising stock price.
Teladoc primarily operates a Business to Business (B2B) model where its primary sales channel is to self-funded employers and other payers. The company generates revenue through subscription fees and licensing its technology platform.
Morningstar’s Equity Analyst Report notes that “Traditional hurdles for the [health information services industry] had been regulatory friction, reimbursement parity, and provider resistance, all of which were temporarily lifted in early 2020. Regulatory friction has historically been a key barrier to the adoption of telehealth.
According to Telehealth.org, “Traditionally, beginning in the 1800s and growing substantially in the 1950s, states have had the authority to license healthcare professionals. States have a vested interest in maintaining that authority because it allows them to exert control over the quality of care given to their citizens by setting standards including the passing of a licensing exam.”
However, as Morningstar notes, the COVID-19 pandemic created a “vacuum for healthcare services.” Consequently, states were forced to loosen restrictions on healthcare providers being able to practice across state lines.
Similarly, public and private plans started to provide reimbursement parity for telehealth visits. Reimbursement parity is when a health insurance plan reimburses a provider equally for a telehealth and in-person visit.
Additionally, the CARES Act added reimbursement codes for telehealth visits and private plans followed suit.
Although immensely profitable for the industry, these changes to the law are temporary and are at risk of reverting to the past once the government declares an end to the health emergency.
Teladoc’s stock price, $91.47 at previous market close (priced less than 50% of fair value), reflects investor uncertainty in the long-term prospects of telehealth. Likewise, Teladoc, despite strong revenue gains in the last five years, has not been profitable.
Beyond the pandemic, the future of telemedicine relies on legislation, specifically targeting reimbursement, parity, and ability to deliver care across state lines.